Phase 2 N=28 Effects of Tolcapone on Frontotemporal Dementia
Frontotemporal Lobar Degeneration
Primary: Reaction Time on the N-back Cognitive Test (0-back Condition) — 7935; 8322 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
Phase 4 N=81 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Frontal Lobe Dementia · Frontotemporal Lobe Dementia · Semantic Dementia
Primary: Change in Neuropsychiatric Inventory (NPI) — -1.9; 0.3 units on a scale
Phase 2 N=16 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Frontotemporal Dementia (FTD)
Primary: Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI) — 7.14; 5.75 score on a scale
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Phase 4 N=127 Corticolimbic Degeneration and Treatment of Dementia
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
N/A N=461 A Family-centered Intervention for Acutely-ill Persons With Dementia
Alzheimer Disease
Primary: Return to Baseline Physical Function Based on the Barthel Index (Change From 2 Weeks Prior to Admission and Changes at Admission, Discharge, and 2 and 6 Months…
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
N/A N=430 Dementia Symptom Management at Home Program
Dementia
Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale
N/A N=104 Improvisational Movement for People With Memory Loss and Their Caregivers
Alzheimer's Disease (Incl Subtypes) · Dementia · Mild Cognitive Impairment
Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale
N/A N=30 Environmental Design for Behavioral Regulation in People With Dementia
Alzheimer Disease
Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12
N/A N=78 In-Home Technology for Dementia Caregivers
Dementia · Alzheimer's Disease · Frontotemporal Dementia
Primary: Zarit Burden Interview-Short Form — 24.58; 25.59 score on a scale
N/A N=66 Care Coordination System for People With Dementia
Alzheimer Disease · Dementia · Dementia Alzheimers
Primary: Change in Baseline Burden and Stress of Caregivers Over 3 Months — -52.0; -31.9 percentage change
N/A N=42 Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Mild Cognitive Impairment · Alzheimer Disease · Vascular Dementia
Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants
Phase 2 N=33 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Frontotemporal Dementia
Primary: Severity of TEAEs — 43; 58; 84; 4 TEAEs (all)
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
N/A N=5,325 Digital Detection of Dementia (D Cubed) Studies: D2
Alzheimer Disease and Related Dementias (ADRD)
Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006
Phase 1 N=161 Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
Primary Progressive Aphasia · Behavioral Variant of Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant
Primary: Proportion of PPA Subjects That Showed Elevated Tau PET Binding Compared to Normal Controls — 3; 0; 17; 0 Participants
N/A N=20 SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Phase 2 N=109 Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Down Syndrome · Amyloid Beta-protein
Primary: Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome…
Phase 3 N=130 The Effect of Diflunisal on Familial Amyloidosis
Familial Amyloid Polyneuropathy · Familial Amyloidosis
Primary: Neurologic Impairment Score + 7 (NIS+7) — 8.2; 26.3; 6.2; 12.5 units on a scale — p=<0.001
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
N/A N=42 ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
Alzheimer Disease
Primary: Acute Safety — 2 participants
N/A N=16 Support Via Technology: Living and Learning With Advancing FTD
Caregivers Burnout · Frontotemporal Dementia
Primary: Revised Memory and Behavior Problems Checklist (RMBPC) — 28.5; 25.2; 16.6; 15.8 units on a scale